drugset / Trial / NCT02474212
: Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery
RandomizedParallel-groupOpen-labelPrevention
Summary
To evaluate the pharmacokinetics of thromboprophylactic doses of LMWH enoxaparin in postoperative CABG patients, drug is administered either as a continuous intravenous infusion (CIV) or subcutaneous bolus (SCB) once per 72h. Plasma anti-Xa values are measured 12-14 times during study period and concentration maximums calculated to enable comparison of anti-Xa values between administration routes.
Timeline
- Start
- 2016-05
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Enoxaparin sodium | Other / unclassified | 0.5 mg/kg | Subcutaneous |
| Comparator | Enoxaparin sodium | Other / unclassified | 1 mg/kg | Subcutaneous |
| Comparator | Enoxaparin sodium | Other / unclassified | 40 mg | Subcutaneous |